MedTrace Logo

An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis

NCT07459660 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2026-04-14

No results posted yet for this study

Summary

ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie, Study ML-007C-MA-221).

Conditions

  • Psychosis Associated With Alzheimer's Disease

Interventions

DRUG

ML-007C-MA

ML-007C-MA dosed as 105/1.5 mg BID or 210/3 mg BID

Sponsors & Collaborators

  • MapLight Therapeutics

    lead INDUSTRY

Principal Investigators

  • MapLight Therapeutics · MapLight Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Max Age
91 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-25
Primary Completion
2029-03-31
Completion
2029-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07459660 on ClinicalTrials.gov